The FINANCIAL — AstraZeneca on October 23 announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of ...

Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. <10yrs: not established. Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Inject immediately after mixing. ≥10yrs: 2mg once ...

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...

Against the backdrop of challenges for its Type 2 diabetes Bydureon business, AstraZeneca has received some good news from the FDA. The U.S. regulatory agency green lit the therapy in children, making ...

(RTTNews) - British drug major AstraZeneca plc (AZN.L, AZN) announced Thursday that the European Commission has approved new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 ...

New formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss Across two clinical trials, average HbA1c reductions of up to 1.4% ...

BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...

(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a ...

WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...

* Astrazeneca PLC - ‍BYDUREON BCise will be available for patients in US in Q1 of 2018 Source text for Eikon: Further company coverage: Sign up here. Autos & Transportationcategory EU executive to ...